This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
by Zacks Equity Research
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
by Zacks Equity Research
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
by Zacks Equity Research
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
by Zacks Equity Research
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 65.41% and 137.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 81.07% and 47.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
by Zacks Equity Research
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
by Zacks Equity Research
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
by Zacks Equity Research
Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
by Zacks Equity Research
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
New Strong Sell Stocks for August 10th
by Zacks Equity Research
ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 24.14% and 3.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.